OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
53.3%−14.3 pts over 5 years
Net margin
3.0%−30.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -2.9% | +0.2% | -1.0% | – | |
| Gross profit | -10.8% | -5.1% | -5.6% | – | |
| Net income | -78.4% | -41.1% | -38.7% | – | |
| EPS, diluted | -78.4% | -41.5% | -39.0% | – | |
| Free cash flow | -29.6% | -6.7% | -23.3% | – | |
| Dividend per share | -69.6% | -32.8% | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 34.5% | 30.6% | |
| Return on assets | – | – | 1.4% | |
| Current ratio | – | 1.33 | 1.82 | |
| Debt to equity | – | 0.00 | 11.49 | |
| Inventory turnover | – | – | 2.1× | |
| Capex to revenue | – | 3.9% | 2.6% | |
| Diluted shares | – | 254M | 261M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Organon generated $5.46B from operations and spent $2.09B on capital expenditure, dividends and share buybacks. 47% of that went back into the business.
Generated
$5.46B
Used
$2.09B
Capital expenditure$976.00M47%Dividends$1.11B53%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.0%
×Asset turnover0.48×
×Equity multiplier21.22×
=Return on equity, FY202530.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.0% | 0.48× | 21.22× | 30.6% |
| FY2024 | 13.5% | 0.51× | 62.58× | 429.9% |
| FY2023 | 16.3% | 0.54× | -23.92× | -212.7% |
| FY2022 | 14.9% | 0.57× | -9.02× | -76.4% |
| FY2021 | 21.4% | 0.61× | 5.23× | 67.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$187.00M
- Cash generatingOperating cash flow above zero$700.00M
- Return on assets improvedROA up on the prior year7.2% → 1.4%
- Earnings backed by cashOperating cash flow above net income$700.00M vs $187.00M
- Less leverageLong-term debt to assets fell67.6% → 67.1%
- Better liquidityCurrent ratio rose1.60 → 1.82
- No dilutionShare count did not rise259M → 261M
- Gross margin improvedGross margin up on the prior year58.02% → 53.30%
- More efficientAsset turnover rose0.53 → 0.47